# Comparison of Injection Site Pain Experience for Semaglutide and Dulaglutide sc

Study · id `cardio:ct-nct04189848` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04189848](<https://clinicaltrials.gov/study/NCT04189848>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04189848

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 104 participants.

## Technical summary

Registry record NCT04189848. Randomized; quadruple masking; primary purpose treatment. Start 2019-12-03 (actual); primary completion 2020-01-29 (actual). Results posted on 2021-02-17.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 104 participants (enrolled count; ClinicalTrials.gov record NCT04189848, source copy `cardio:ctgov-nct04189848-2022-11-07`, retrieved 2026-10-26)
- Started: 2019-12-03 (actual) (ClinicalTrials.gov record NCT04189848, source copy `cardio:ctgov-nct04189848-2022-11-07`, retrieved 2026-10-26)
- Primary completion: 2020-01-29 (actual) (ClinicalTrials.gov record NCT04189848, source copy `cardio:ctgov-nct04189848-2022-11-07`, retrieved 2026-10-26)
- Completion: 2020-02-27 (actual) (ClinicalTrials.gov record NCT04189848, source copy `cardio:ctgov-nct04189848-2022-11-07`, retrieved 2026-10-26)
- Results first posted: 2021-02-17 (ClinicalTrials.gov record NCT04189848, source copy `cardio:ctgov-nct04189848-2022-11-07`, retrieved 2026-10-26)
- Countries: Netherlands (ClinicalTrials.gov record NCT04189848, source copy `cardio:ctgov-nct04189848-2022-11-07`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04189848-2022-11-07`, retrieved 2026-10-26)

## The registry's words

- Brief title: Comparison of Injection Site Pain Experience for Semaglutide and Dulaglutide sc
- Condition: Healthy Volunteers
- Condition: Diabetes Mellitus, Type 2
- Condition: Overweight
- Condition: Obesity
- Intervention (Drug): Semaglutide
- Intervention (Drug): Dulaglutide
- Lead sponsor: Novo Nordisk A/S
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry intervention name matches this record: Semaglutide (`cardio:semaglutide`)
- Registry lists this organization as the lead sponsor: Novo Nordisk (`cardio:novo-nordisk`)

### Other papers using this trial's data

- Registry lists this paper as a reference of type result; PubMed dates it on or after the trial start and types it as a trial report, neither its types nor its title mark it as a protocol, a review or a comment, the paper names no other trial in place of this one, and PubMed shows no retraction or expression of concern; it is not marked as the trial's main report: Comparison of the injection-site experience of the starting doses with semaglutide and dulaglutide: A randomized, double-blind trial in healthy subjects (`cardio:pubmed-33591618`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 22da4dfe332a08a06c27474ad06841e470d5b6fa1e9619cef0aa68070b55450c
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
